Business in the Burbs

Taro drug gets tentative approval for fungal infections treatment

March

Taro Pharmaceutical Industries Ltd., an Israel-based company with operations in Hawthorne, said this morning that it has gotten tentative federal approval for a product that treats fungal infections of the nails.

The U.S. Food and Drug Administration has determined that Ciclopirox is safe and effective compared with a product made by Sanofi-Aventi Pharmaceuticals. That product has annual sales in the United States of $88 million, Taro said.

Taro said the approval means it can market the product when patents and other restrictions expire, which is expected to happen in September.

Taro shares closed yesterday at $8.50, down 5 cents.

This entry was posted on Tuesday, March 27th, 2007 at 12:03 pm by Allan Drury.
You can follow any responses to this entry through the RSS 2.0 feed.
Print | Email

It is a condition of your use of the comment features associated with the blogs that you do not: Use the site to post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including without limitation any transmissions constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or international law. You alone are responsible for the material you post or send. Refer to the Terms of Service.